López-Díaz, ÁlvaroMurillo-Izquierdo, ManuelMoreno-Mellado, Elisa2023-01-252023-01-252019-04-29http://hdl.handle.net/10668/13886Ketamine therapy for treatment-resistant depression in European national health systems may only be considered after attempting all evidence-based antidepressant strategies outlined in clinical guidelines. This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system.Declaration of interestNone.enTreatment-resistant depressionantidepressantsketamineAntidepressive AgentsDepressive Disorder, Treatment-ResistantEuropeHumansKetamineOff-Label UsePractice Guidelines as TopicSafetyresearch article31030677open access10.1192/bjp.2019.1021472-1465https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7E343DF5A137842625DC6709CD011F39/S0007125019001028a.pdf/div-class-title-off-label-use-of-ketamine-for-treatment-resistant-depression-in-clinical-practice-european-perspective-div.pdf